Email

slerner@bcm.edu

Positions

Professor

Urology
Baylor College of Medicine
Houston, TX US
Beth and Dave Swalm Chair in Urologic Oncology Director of Urologic Oncology Director of the Multidisciplinary Bladder Cancer Program

Addresses

Baylor College of Medicine Medical Center (Clinic)

7200 Cambridge, Suite 10B
Houston, TX 77030
United States
Phone: (713) 798-4001

Education

B.A. from University Of Texas At Austin

01/1979 - Austin, TX United States

M.D. from Baylor College Of Medicine

01/1984 - Houston, TX United States

Internship at Virginia Mason Hospital

01/1985 - Seattle, Washington United States

Residency at Virginia Mason Hospital

06/1986 - Seattle, Washington United States

General Surgery

Residency at Baylor College of Medicine

06/1990 - Houston, Texas United States

Urology

Fellowship at University Of Southern California

06/1992 - Los Angeles, California United States

Urologic Oncology

Certifications

American Board of Urology

Professional Interests

• Urologic Oncology and Reconstructive Surgery with Interest in Minimally Invasive Surgery

Professional Statement

Seth P. Lerner, MD, is Professor of Urology and holds the Beth and Dave Swalm Chair in Urologic Oncology, in the Scott Department of Urology, Baylor College of Medicine. He is Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program and Faculty Group Practice Medical Director for the Urology Clinic.

He earned his medical degree from Baylor College of Medicine, completed a surgical internship at Virginia Mason Hospital in Seattle, and returned to Baylor for his residency training. He completed a two-year fellowship at the University of Southern California in urologic oncology and reconstructive surgery under Peter Jones and Don Skinner before returning to join the full-time Baylor faculty in 1992. His clinical practice, education, and research activities are devoted to urologic oncology and particularly lower and upper tract urothelial cancer.

Dr. Lerner is author of over190 peer-reviewed articles, and co-editor of a comprehensive Textbook of Bladder Cancer. He is the founding co-editor-in-chief of the Bladder Cancer journal. He established and directs the multi-disciplinary Bladder Cancer Research Program at Baylor and his research interests include use of selective estrogen receptor modulators for treatment of bladder cancer, gene therapy, integrated genomic analysis of bladder and upper urinary tract cancers, and outcomes of radical cystectomy and pelvic lymphadenectomy. He has 26 years experience as a clinical investigator for both NCI and industry funded clinical trials. He is the PI of the ongoing SWOG NCI Phase III trial comparing extended vs. standard pelvic lymphadenectomy at time of radical cystectomy. He is active in the leadership of several national bladder cancer research enterprises including chair of the Local Bladder Cancer committee of SWOG, founding and former co-chair of the NCI Bladder Cancer Task Force and current co-chair of the NCI CTEP Genitourinary Steering Committee, and he has co-chaired the Analysis Working Group of The Cancer Genome Atlas Project for muscle invasive bladder cancer for the past 7 years. He is very active in the Bladder Cancer Advocacy Network (BCAN) as a member of the Board of Directors, past chair of the Bladder Cancer Think Tank and co-chair of the management committee of the Bladder Cancer Research Network. Dr. Lerner is an active member of the prestigious American Association of Genitourinary Surgeons and is listed routinely among “America’s Top Doctors” and “Best Doctors in America.

Websites

Selected Publications

• Levitt JM, Jian W, Lerner SP, Sonpavde G "A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma.." Urol. Oncol.. 2013 Feb;31(2):234-40. Pubmed PMID: 21723160
• Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, Aimi J, Lerner S, Yeung AW, Kazarian T, Maslyar DJ, McKiernan JM "A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer.." J. Urol.. 2012 Dec;188(6):2391-7. Pubmed PMID: 23088985
• Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T, Sternberg CN, Sonpavde G "A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer.." Eur. Urol.. 2012 Sep;62(3):523-33. Pubmed PMID: 22677572
• Jian PY, Godoy G, Coburn M, Lynch G, Ro JY, Zhai QJ, Nishino M, Lerner SP "Adenocarcinoma following urinary diversion.." Can Urol Assoc J. 2012 Apr;6(2):E77-80. Pubmed PMID: 22511440

Memberships

American Association of Genitourinary Surgeons

Member

American Urological Association

Member

American Association for Cancer Research

Member

American Association for the Advancement of Science

Member

American College of Surgeons

Fellow

American Medical Association

Member

American Society of Clinical Oncology

Member

American Society of Gene Therapy

Member

American Association of Clinical Urologists

Member

Harris County Medical Society

Member

International Bladder Cancer Network

Member

Society of Basic Urologic Research

Member

Société International D’Urologie

Member

Society of Laparoendoscopic Surgeons

Member

South Central Section of the American Urological Association

Member

Society of University Urologists

Member

Southwest Oncology Group

Member

Texas Urological Society

Member

Texas Medical Association

Member

Skills

Research Interests

Bladder Cancer Collaborative Research Program: Role of estrogen receptors and the use of selective estrogen receptor modulators (e.g., tamoxifen) for treatment of bladder cancer; novel targeted therapeutics and gene therapy for treatment of non-muscle-invasive and invasive disease; outcome of treatments for non-muscle-invasive bladder cancer and radical cystectomy and development of predictive models; genomic characterization and integrated analysis of bladder and upper tract cancers

Clinical Interests

Urologic oncology and urinary tract reconstruction; management of patients with bladder, prostate, testis and kidney cancer; Director, Bladder Cancer Multidisciplinary Clinical Program

Clinical Trials

Bladder cancer; prostate cancer; kidney cancer